1
|
Bardol T, Eslami‐S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, Bobrie A, D'Hondt V, Guiu S, Kurma K, Cayrefourcq L, Jacot W, Alix‐Panabières C. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study. Cancer Med 2023; 13:e6843. [PMID: 38132919 PMCID: PMC10807582 DOI: 10.1002/cam4.6843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 11/07/2023] [Accepted: 11/25/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND For several years, the AXL tyrosine kinase receptor, a member of the Tyro3-Axl-Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL+ CTCs) could be clinically relevant. METHODS Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment initiation. RESULTS An innovative AXL+ CTC detection assay to be used with the CellSearch® system was developed. In a prospective longitudinal clinical trial, blood samples from 60 patients with untreated mBC were analyzed to detect AXL+ CTCs with this new assay. CTCs were detected in 35/60 patients (58.3%) and AXL+ CTCs were identified in 7 of these 35 patients (11.7% of all patients). CONCLUSION This newly established AXL+ CTC assay is a promising tool that can be used for liquid biopsy in future clinical trials to stratify and monitor patients with cancer receiving anti-AXL therapies.
Collapse
Affiliation(s)
- Thomas Bardol
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
| | - Zahra Eslami‐S
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
- European Liquid Biopsy Society (ELBS)HamburgGermany
| | - Doryan Masmoudi
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
| | - Marie Alexandre
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Marie Duboys de Labarre
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Angélique Bobrie
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Véronique D'Hondt
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Séverine Guiu
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Keerthi Kurma
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
- European Liquid Biopsy Society (ELBS)HamburgGermany
| | - Laure Cayrefourcq
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
- European Liquid Biopsy Society (ELBS)HamburgGermany
| | - William Jacot
- Department of Medical OncologyInstitut du Cancer de Montpellier, Montpellier UniversityMontpellierFrance
- Institut de Recherche en Cancérologie de MontpellierINSERM U1194, Montpellier UniversityMontpellierFrance
| | - Catherine Alix‐Panabières
- Laboratory of Rare Circulating Human Cells—University Medical Center of MontpellierMontpellierFrance
- CREEC/CANECEV, MIVEGEC (CREES)Université de Montpellier, CNRS, IRDMontpellierFrance
- European Liquid Biopsy Society (ELBS)HamburgGermany
| |
Collapse
|
2
|
Affiliation(s)
- Catherine Alix‐Panabières
- Laboratory of Rare Human Circulating Cells (LCCRH)University Medical Centre of MontpellierMontpellierFrance
- CREEC/CANECEVMIVEGEC (CREES)University of MontpellierCNRSIRDMontpellierFrance
| | - Klaus Pantel
- Department of Tumor BiologyUniversity Cancer Center HamburgUniversity Medical Center Hamburg‐EppendorfHamburgGermany
| |
Collapse
|
3
|
Dujon AM, Aktipis A, Alix‐Panabières C, Amend SR, Boddy AM, Brown JS, Capp J, DeGregori J, Ewald P, Gatenby R, Gerlinger M, Giraudeau M, Hamede RK, Hansen E, Kareva I, Maley CC, Marusyk A, McGranahan N, Metzger MJ, Nedelcu AM, Noble R, Nunney L, Pienta KJ, Polyak K, Pujol P, Read AF, Roche B, Sebens S, Solary E, Staňková K, Swain Ewald H, Thomas F, Ujvari B. Identifying key questions in the ecology and evolution of cancer. Evol Appl 2021; 14:877-892. [PMID: 33897809 PMCID: PMC8061275 DOI: 10.1111/eva.13190] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 12/24/2020] [Accepted: 12/26/2020] [Indexed: 12/17/2022] Open
Abstract
The application of evolutionary and ecological principles to cancer prevention and treatment, as well as recognizing cancer as a selection force in nature, has gained impetus over the last 50 years. Following the initial theoretical approaches that combined knowledge from interdisciplinary fields, it became clear that using the eco-evolutionary framework is of key importance to understand cancer. We are now at a pivotal point where accumulating evidence starts to steer the future directions of the discipline and allows us to underpin the key challenges that remain to be addressed. Here, we aim to assess current advancements in the field and to suggest future directions for research. First, we summarize cancer research areas that, so far, have assimilated ecological and evolutionary principles into their approaches and illustrate their key importance. Then, we assembled 33 experts and identified 84 key questions, organized around nine major themes, to pave the foundations for research to come. We highlight the urgent need for broadening the portfolio of research directions to stimulate novel approaches at the interface of oncology and ecological and evolutionary sciences. We conclude that progressive and efficient cross-disciplinary collaborations that draw on the expertise of the fields of ecology, evolution and cancer are essential in order to efficiently address current and future questions about cancer.
Collapse
Affiliation(s)
- Antoine M. Dujon
- School of Life and Environmental SciencesCentre for Integrative EcologyDeakin UniversityWaurn PondsVic.Australia
- CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRDMontpellierFrance
| | - Athena Aktipis
- Biodesign InstituteDepartment of PsychologyArizona State UniversityTempeAZUSA
| | - Catherine Alix‐Panabières
- Laboratory of Rare Human Circulating Cells (LCCRH)University Medical Center of MontpellierMontpellierFrance
| | - Sarah R. Amend
- Brady Urological InstituteThe Johns Hopkins School of MedicineBaltimoreMDUSA
| | - Amy M. Boddy
- Department of AnthropologyUniversity of California Santa BarbaraSanta BarbaraCAUSA
| | - Joel S. Brown
- Department of Integrated MathematicsMoffitt Cancer CenterTampaFLUSA
| | - Jean‐Pascal Capp
- Toulouse Biotechnology InstituteINSA/University of ToulouseCNRSINRAEToulouseFrance
| | - James DeGregori
- Department of Biochemistry and Molecular GeneticsIntegrated Department of ImmunologyDepartment of PaediatricsDepartment of Medicine (Section of Hematology)University of Colorado School of MedicineAuroraCOUSA
| | - Paul Ewald
- Department of BiologyUniversity of LouisvilleLouisvilleKYUSA
| | - Robert Gatenby
- Department of RadiologyH. Lee Moffitt Cancer Center & Research InstituteTampaFLUSA
| | - Marco Gerlinger
- Translational Oncogenomics LabThe Institute of Cancer ResearchLondonUK
| | - Mathieu Giraudeau
- CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRDMontpellierFrance
- Littoral Environnement et Sociétés (LIENSs)UMR 7266CNRS‐Université de La RochelleLa RochelleFrance
| | | | - Elsa Hansen
- Center for Infectious Disease Dynamics, Biology DepartmentPennsylvania State UniversityUniversity ParkPAUSA
| | - Irina Kareva
- Mathematical and Computational Sciences CenterSchool of Human Evolution and Social ChangeArizona State UniversityTempeAZUSA
| | - Carlo C. Maley
- Arizona Cancer Evolution CenterBiodesign Institute and School of Life SciencesArizona State UniversityTempeAZUSA
| | - Andriy Marusyk
- Department of Cancer PhysiologyH Lee Moffitt Cancer Centre and Research InstituteTampaFLUSA
| | - Nicholas McGranahan
- Translational Cancer Therapeutics LaboratoryThe Francis Crick InstituteLondonUK
- Cancer Research UK Lung Cancer Centre of ExcellenceUniversity College London Cancer InstituteLondonUK
| | | | | | - Robert Noble
- Department of Biosystems Science and EngineeringETH ZurichBaselSwitzerland
- Department of Evolutionary Biology and Environmental StudiesUniversity of ZurichZurichSwitzerland
| | - Leonard Nunney
- Department of Evolution, Ecology, and Organismal BiologyUniversity of California RiversideRiversideCAUSA
| | - Kenneth J. Pienta
- Brady Urological InstituteThe Johns Hopkins School of MedicineBaltimoreMDUSA
| | - Kornelia Polyak
- Department of Medical OncologyDana‐Farber Cancer InstituteBostonMAUSA
- Department of MedicineHarvard Medical SchoolBostonMAUSA
| | - Pascal Pujol
- CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRDMontpellierFrance
- Centre Hospitalier Universitaire Arnaud de VilleneuveMontpellierFrance
| | - Andrew F. Read
- Center for Infectious Disease DynamicsHuck Institutes of the Life SciencesDepartments of Biology and EntomologyPennsylvania State UniversityUniversity ParkPAUSA
| | - Benjamin Roche
- CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRDMontpellierFrance
- Unité Mixte Internationale de Modélisation Mathématique et Informatique des Systèmes ComplexesUMI IRD/Sorbonne UniversitéUMMISCOBondyFrance
| | - Susanne Sebens
- Institute for Experimental Cancer Research Kiel University and University Hospital Schleswig‐HolsteinKielGermany
| | - Eric Solary
- INSERM U1287Gustave RoussyVillejuifFrance
- Faculté de MédecineUniversité Paris‐SaclayLe Kremlin‐BicêtreFrance
| | - Kateřina Staňková
- Department of Data Science and Knowledge EngineeringMaastricht UniversityMaastrichtThe Netherlands
- Delft Institute of Applied MathematicsDelft University of TechnologyDelftThe Netherlands
| | | | - Frédéric Thomas
- CREEC/CANECEV, MIVEGEC (CREES), University of Montpellier, CNRS, IRDMontpellierFrance
| | - Beata Ujvari
- School of Life and Environmental SciencesCentre for Integrative EcologyDeakin UniversityWaurn PondsVic.Australia
| |
Collapse
|